Inmune Bio (NASDAQ: INMB) director exercises 14,801 warrants at $1.40

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Inmune Bio, Inc. director Juda Scott exercised common stock purchase warrants in a cash transaction, acquiring 14,801 shares of Common Stock at $1.40 per share. This exercise stems from an April 2024 warrant inducement agreement with the company.

Following the transaction, Scott directly owns 86,404 shares of Common Stock. Under the same inducement letter, the maturity date of the remaining 50% of Scott’s April 2024 warrants that were not exercised was extended from June 30, 2026 to December 31, 2027, providing a longer exercise window for those warrants.

Insider Trade Summary

14,801 shares exercised/converted

Mixed 2 txns

Insider Juda Scott

Role null

Type	Security	Shares	Price	Value
X	Common Stock Purchase Warrant	14,801	$0.125	$2K
Exercise	Common Stock	14,801	$1.40	$21K

Holdings After Transaction: Common Stock Purchase Warrant — 14,802 shares (Direct, null); Common Stock — 86,404 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Common shares acquired: 14,801 shares Exercise price: $1.40 per share Director holdings after transaction: 86,404 shares +4 more

7 metrics

Common shares acquired 14,801 shares Shares of Common Stock acquired via warrant exercise on July 2, 2026

Exercise price $1.40 per share Cash exercise price for April 2024 warrants

Director holdings after transaction 86,404 shares Total Common Stock directly owned by Juda Scott after exercise

Warrants exercised 14,801 warrants April 2024 Warrants exercised representing 50% of Scott’s holdings

Extended warrant expiration December 31, 2027 New maturity date for remaining 50% of April 2024 Warrants

Original warrant expiration June 30, 2026 Prior maturity date for unexercised April 2024 Warrants

Warrant transaction price figure $0.1250 Price figure associated with derivative transaction entry for warrants

Key Terms

Common Stock Purchase Warrant, warrant inducement offer letter agreement, April 2024 Warrants, exercise price, +1 more

5 terms

Common Stock Purchase Warrant financial

"Represents 14,801 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person."

A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.

warrant inducement offer letter agreement financial

"entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter")."

April 2024 Warrants financial

"previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants")."

exercise price financial

"agreed to purchase 14,801 shares of common stock at a reduced exercise price of $1.40"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

maturity date financial

"in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants"

The maturity date is the specific day when a loan, bond, or investment reaches its full term and the borrower must repay the borrowed amount in full. It is important for investors because it indicates when they will receive their initial money back and can plan their future financial steps accordingly. Think of it as the due date for a loan or the day a gift card or coupon expires.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/07/2026 - 07:02 AM Accepted by SEC EDGAR 07/07/2026 - 07:01 AM

FAQ

What did Inmune Bio (INMB) director Juda Scott report in this Form 4?

Juda Scott reported exercising warrants to acquire 14,801 Inmune Bio common shares. The exercise was a cash transaction at $1.40 per share, increasing Scott’s direct holdings to 86,404 common shares and forming part of a broader April 2024 warrant inducement arrangement.

How many Inmune Bio (INMB) shares does Juda Scott hold after the reported transactions?

After the transactions, Juda Scott directly holds 86,404 Inmune Bio common shares. This total reflects the addition of 14,801 shares acquired through exercising common stock purchase warrants pursuant to the April 2024 warrant inducement letter agreement with the company.

At what price did Juda Scott exercise Inmune Bio (INMB) warrants on this Form 4?

Scott exercised Inmune Bio common stock purchase warrants at an exercise price of $1.40 per share. The exercise covered 14,801 warrants, resulting in the same number of common shares being issued to Scott in a cash exercise under the inducement agreement.

What are the key terms of the April 2024 warrant inducement for Inmune Bio (INMB)?

Under the inducement, Scott agreed to exercise 14,801 April 2024 warrants for cash at $1.40 per share. In return, Inmune Bio extended the maturity date of the remaining 50% of Scott’s April 2024 warrants from June 30, 2026 to December 31, 2027.

Did Juda Scott sell any Inmune Bio (INMB) shares in this Form 4 filing?

No, the Form 4 shows only warrant exercises and share acquisitions, with no sales. Scott exercised 14,801 common stock purchase warrants for cash to receive the same number of common shares, increasing direct share ownership without reporting any dispositions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Juda Scott

(Last)

(First)

(Middle)

C/O INMUNE BIO INC.

225 NE MIZNER BLVD., SUITE 640

(Street)

BOCA RATON

FLORIDA

33432

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inmune Bio, Inc. [ INMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/02/2026		M		14,801⁽¹⁾	A	$1.4	86,404	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock Purchase Warrant	$1.4	07/02/2026		X			14,801	07/02/2026	12/31/2027	Common Stock	14,801	$0.125	14,802	D

Explanation of Responses:

1. Represents 14,801 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 14,801 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 14,801 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027.

	/s/ Scott Juda	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR